Financial Performance - The company's net profit attributable to shareholders is expected to be approximately ¥1,172.66 million, a decrease of 70.90% compared to ¥4,030.15 million in the same period last year[3]. - Revenue is projected to decline by 10.38% due to factors such as global economic development and a slowdown in export trade, with hearing aid product sales maintaining over 90% of total revenue[4]. Expenses - Management expenses increased by ¥6.8565 million due to the completion and operation of the JinHao Smart Medical Industrial Park and an increase in personnel[4]. - R&D expenses rose by ¥7.99 million as the company continues to invest in product development and talent acquisition[5]. Impairment and Risks - The company has recognized a credit impairment loss of ¥6.5403 million due to a decline in terminal demand from some customers amid high inflation and ongoing interest rate hikes in Europe and the U.S.[5]. - The performance forecast is based on preliminary calculations and has not been audited by an accounting firm, emphasizing the need for cautious investment decisions[6].
锦好医疗(872925) - 2023 Q4 - 年度业绩预告